TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01565889
Drug: EFV/FTC/TDF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efavirenz (EFV) 600 mg/emtricitabine (FTC) 200 mg/tenofovir disoproxil fumarate (TDF) 300 mg fixed-dose combination (FDC) tablet administered orally once daily
Study: NCT01565889
Drug: ZDV/3TC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zidovudine (ZDV) 300 mg/lamivudine (3TC) 150 mg FDC tablet administered orally twice daily
Study: NCT01565889
Drug: FTC/TDF
Approvals — FDA: no, EMA: no, PMDA: no
Description: FTC/TDF (200/300 mg) FDC tablet administered orally once daily
Study: NCT01565889
Drug: DRV
Normalized name: Urinal Male Drv RTLPC23201
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darunavir (DRV) 800 mg (2 × 400 mg tablets) administered orally once daily
Study: NCT03950154
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine oral agent
Study: NCT00810147
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules, Oral, 0 mg, once daily, 24 weeks
Study: NCT03248427
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60 mg/m2 as a continuous IV perfusion
Study: NCT03248427
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 600 MG/M2 in a 30 minutes IV infusion
Study: NCT00051948
Drug: TLK286
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00185289
Drug: EV/DNG (Qlaira, BAY86-5027, SH T00658K)
Approvals — FDA: no, EMA: no, PMDA: no
Description: per cycle (28 days): Days 1-2: 3.0 mg EV; Days 3-7: 2.0 mg EV + 2.0 mg DNG; Days 8-24: 2.0 mg EV + 3.0 mg DNG; Days 25-26: 1.0 mg EV; Days 27-28: Placebo
Study: NCT00999986
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 50 mg oral per day for 7 days
Study: NCT00238966
Drug: Enteric-Coated Mycophenolate Sodium (EC-MPS)
Normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02565680
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xyzall 5mg during 5 days + placebo 40mg during 4 days
Study: NCT03591874
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opthalmic buffered saline solution Eye Drops given 2 times a day for 12 weeks.
Study: NCT00695344
Drug: azathioprine or mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2 times per day during 2 years
Study: NCT02477644
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets, per os, 300 mg twice daily.
Study: NCT00127114
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00894621
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Solution administration contend titrated norepinephrine in doses of 0,1 to 0,4 mc/kg/min. Initiated solution 24 hours after beginning mechanical ventilation. Use of the solution during 72 hours.
Study: NCT00894621
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01710787
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 unilateral intranasal sprays per dose
Study: NCT01467297
Drug: ceftidoren
Approvals — FDA: no, EMA: no, PMDA: no
Description: ceftidoren 200 mg bid for 5 days
Study: NCT03408639
Drug: CinnaPoietin®
Approvals — FDA: no, EMA: no, PMDA: no
Description: The starting dose of Erythropoietin is 60 (50-100) IU/kg body weight/week for naïve patients. Administration dose for patients who are treated with erythropoietin is similar dose of previously administered amount (IV or SC without any change). After then, dose adjustment will be done based on patients' response.
Study: NCT03408639
Drug: Eprex®
Approvals — FDA: no, EMA: no, PMDA: no
Description: The starting dose of Erythropoietin is 60 (50-100) IU/kg body weight/week for naïve patients. Administration dose for patients who are treated with erythropoietin is similar dose of previously administered amount (IV or SC without any change). After then, dose adjustment will be done based on patients' response.
Study: NCT03408639
Drug: Nephrovit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nephrovit tablet is daily administered to all the patients.
Study: NCT03766295
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01026194
Drug: Placebo / Teneli (Teneligliptin) + pio (pioglitazone)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for 12 weeks (double-blind period) followed by teneligliptin for an additional 40 weeks (open-label period) in combination with pioglitazone.
Study: NCT01026194
Drug: Teneli / Teneli + pio
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teneligliptin for 12 weeks (double-blind period) followed by teneligliptin for an additional 40 weeks (open-label period) in combination with pioglitazone.
Study: NCT01315431
Drug: Tesetaxel plus capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Study medication, which will include tesetaxel capsules and capecitabine tablets, will be administered orally for two 21-day cycles. In each cycle, tesetaxel will be administered at a dose of 27 mg/m2 on Day 1, and capecitabine will be administered in Cohort 1 at a dose of 2000 mg/m2/day and in Cohort 2 at a dose of 1750 mg/m2/day (in 2 equally divided doses) on Day 1 through Day 14.~At the conclusion of Cycle 2, patients who, in the opinion of the investigator, appear to have benefitted from protocol therapy may receive up to 6 additional cycles under a separate protocol.
Study: NCT04464850
Drug: Intravenous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron sucrose will be given by continuous infusion for 1 hour during the last 1 hour of dialysis session. Iron sucrose will be given for 24 weeks during study period.~Serum ferritin will be monitored at 4, 12, and 24 weeks after randomization.~The dosage of intravenous iron will be adjusted according to serum ferritin levels as follows.~Serum ferritin \<500 mg/dl: iron sucrose 100 mg every 2 weeks Serum ferritin 500-800 mg/dl: iron sucrose 100 mg every 4 weeks Serum ferritin \>800 mg/dl: discontinue iron sucrose
Study: NCT04464850
Drug: Oral iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet, three times a day, of iron fumarate will be prescribed for 24 weeks of study period.~The dosage of iron fumarate will be adjusted according to serum ferritin levels as follows.~Serum ferritin will be monitored at 4, 12, and 24 weeks after randomization.~Serum ferritin \<500 mg/dl: iron fumarate 200 mg three times daily Serum ferritin 500-800 mg/dl: iron fumarate 200 mg once daily Serum ferritin \>800 mg/dl: discontinue iron fumarate
Study: NCT00742209
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo-control
Study: NCT00835393
Drug: PROTONIX® 40 mg delayed-release tablets.
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 x 40 mg
Study: NCT02562066
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A placebo equivalent will be provided as tablets indistinguishable from the amifampridine phosphate tablets. The placebo will be administered consistent with the dose regimen of amifampridine phosphate.
Study: NCT03843060
Drug: AZD9977
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive single AZD9977 (Dose 1) capsule orally once daily in fed state, on Day 1 followed by at least 3 days washout period.
Study: NCT00638508
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive Ketorolac at 5 mg/hr not to exceed 120 mg/day
Study: NCT00638508
Drug: Ketorolac and Ropivacaine
Normalized name: phenylephrine and ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive Ketorolac at 5 mg/hr plus 0.5% Ropivacaine
Study: NCT03327844
Drug: RET using non-setting Calcium Hydroxide
Normalized name: Calcium Hydroxide
Approvals — FDA: no, EMA: no, PMDA: no
Description: First Treatment Visit: Local analgesic, Tooth isolation, access, pulp extirpation and root canal irrigation with 1.5% sodium hypochlorite. Canal negotiation, canal drying using paper points. Delivery of the non-setting Calcium Hydroxide. Tooth access sealed with temporary dressing. Second Treatment Visit: Tooth analgesia using plain local analgesics without vasoconstrictor, isolation and re-access as described above. Irrigation of root canal system using sodium hypochlorite followed by paper point drying. Initiation of bleeding through insertion of a sterile k-file at a length of 2-3 mm beyond the working length into the periapical tissues. Access sealed using resorbable plug, Biodentine, followed by composite resin.
Study: NCT04347720
Drug: Indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous formulation
Study: NCT04347720
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous and oral formulations
Study: NCT04347720
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous and oral formulations
Study: NCT00918424
Drug: Oxcarbazepine Extended Release
Normalized name: oxcarbazepine Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: OXC XR is a once-daily formulation of oxcarbazepine and is given at the same dosage levels.
Study: NCT02440464
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Between 60 and 120 days following HSCT, patients randomized to the control group will be given 3 mg of placebo orally on Days 1, 8, and 15 of a 28-day cycle. This will increase to 4-mg doses on the same cycle schedule following successful completion of 3 cycles of placebo maintenance at the 3-mg dose. This will continue for a total of 12 cycles.
Study: NCT03158103
Drug: MEK162
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEK162 at 30mg twice daily
Study: NCT02001987
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate will be administered at a stable dose that was initiated at least 4 weeks prior to Baseline, at investigator's discretion.
Study: NCT02001987
Drug: csDMARDs
Approvals — FDA: no, EMA: no, PMDA: no
Description: csDMARDs (at investigator's discretion) will be administered at a stable dose that was initiated at least 4 weeks prior to Baseline, at investigator's discretion.
Study: NCT02862236
Drug: Hypericum perforatum extract
Normalized name: Hypericum perforatum extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 or 500 mg Remotiv capsules of hypericum perforatum extract, p.o.
Study: NCT00489866
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Same as active drug.
Study: NCT02845648
Drug: anticholinergic
Normalized name: Anticholinergics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial anticholinergic therapy to all patients
Study: NCT02635984
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet taken by mouth once daily on chemotherapy days and for 3 days post chemotherapy
Study: NCT02770378
Drug: Minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Induction cycle day 3-4: minocycline 50 mg p.o. twice daily from day 19-20; minocycline 100 mg p.o. twice daily during treatment cycle 1-12 (28 days); minocycline 100 mg p.o. twice daily
Study: NCT02770378
Drug: Disulfiram
Normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Induction cycle day 5-6: disulfiram 250 mg p.o. once daily from day 21-22; disulfiram 250 mg p.o. twice daily during treatment cycle 1-12 (28 days); disulfiram 250 mg p.o. twice daily
Study: NCT02770378
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Induction cycle day 1-35: day 7-8: celecoxib 200 mg p.o. twice daily from day 23-24; celecoxib 400 mg p.o. twice daily during treatment cycle 1-12 (28 days); celecoxib 400 mg p.o.twice daily
Study: NCT01306266
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial treatment with placebo followed by treatment with Maxalt-MLT 10 mg at onset of a moderate or severe headache.
Study: NCT01110590
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04311294
Drug: Matched Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: ANS-6647 is a selective, reversible, and orally bioavailable aldehyde dehydrogenase 2 (ALDH2) inhibitor. It will be tested at a low dose (200mg) and a high dose (600mg) against matched placebo.
Study: NCT00422604
Drug: GSK233705
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04074187
Drug: Corticosteroid treatment (Methylprednisolone or prednisolone)
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:Solution for injection or Tablet Route of administration: IV or Oral
Study: NCT04074187
Drug: Immunosuppressive treatment (eg, rituximab)
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:Solution for injection (depending on product) Route of administration: IV (depending on product)
Study: NCT00697632
Drug: MGCD265
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral daily administration without interruption
Study: NCT00651274
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablets: placebo to match ezetimibe 10 mg once daily for 6 weeks (plus continued simvastatin)
Study: NCT04376931
Drug: Intravenous Solution
Normalized name: Intravenous Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iscador®P: fermented aqueous extract of mistletoe grown on pine tree (Viscum album L. subspecies austriacum (Wiesb.) Vollmann), licensed for subcutaneous (SC) application in Switzerland, Germany, Austria, Sweden, and South Korea in dosages up to 20 mg.
Study: NCT02912182
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo intravenous NaCl intravenous administration Placebo tablets
Study: NCT02912182
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral tablets
Study: NCT02690038
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline Ig \< 7g/L group - Normal Saline (0.9% NaCl) 8 mL/kg will be given within 12 hours after randomization.~Baseline Ig \> or = 7 g/L group - Normal Saline (0.9% NaCl) 5 mL/kg will be given within 12 hours after randomization
Study: NCT01406587
Drug: PP4001
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg, 1 dose every 12 hours x 4 doses
Study: NCT01406587
Drug: PP4001
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg, 1 dose every 12 hours x 4 doses
Study: NCT01406587
Drug: PP4001
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg, 1 dose every 12 hours x 4 doses
Study: NCT01406587
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, 1 dose every 12 hours x 4 doses
Study: NCT00395161
Drug: Zinc
Normalized name: Zinc
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: one enteral dose daily of zinc chloride (10 mg/day elemental zinc for infants \< or equal to one year of age, and 20 mg/day elemental zinc for patients \> 1 year of age)
Study: NCT00003627
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03774355
Drug: CG1801
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration CG1801 2mg single dose in phase 1 and Administration CGL1802 2mg single dose phase 2.
Study: NCT03774355
Drug: CGL1802
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration CGL1802 2mg single dose in phase 1 and Administration CG1801 2mg single dose phase 2
Study: NCT01595347
Drug: Hyper-oxigenated fatty acid
Normalized name: Hyper-Sal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aplicación tópica de Mepentol (R) en zonas de riesgo de úlceras por presión (sacro, caderas y talones) 1 aplicación/24 horas
Study: NCT03867097
Drug: Placebo IV infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study drug will be initiated at a starting dose of 0.5 ng/kg/min up to 2.0 ng/kg/min. Subjects will receive study drug for 5 consecutive days as an IV infusion over 6 hours each day via a peripheral line.
Study: NCT02562573
Drug: PBI4050
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03289819
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: All patients will receive 12 cycles of weekly nab-paclitaxel intravenous (i.v.) 125 mg/m² body surface area (BSA) in combination with 4 cycles of pembrolizumab i.v. 200 mg q3w; followed by 4 cycles of epirubicin i.v. 90 mg/m² BSA and cyclophosphamide i.v. 600 mg/m² BSA, q3w in combination with 4 cycles of pembrolizumab i.v. 200 mg/kg q3w.
Study: NCT00550459
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet given once daily for 21 days
Study: NCT00033397
Drug: chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01742897
Drug: TTS-fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00254592
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60 mg/m2 IV, bolus once a day every 14 days x 2-4 cycles
Study: NCT00254592
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 600 mg/m2 IV once a day every 14 days x 2-4 cycles
Study: NCT02962986
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Norepinephrine diluted in 5% dextrose solution to a concentration of 6mcg/mL
Study: NCT01508884
Drug: Aqueous cream
Normalized name: Pen-Aqueous
Approvals — FDA: no, EMA: no, PMDA: no
Description: pretreatment with topical aqueous cream to the injection site before vaccination
Study: NCT00266279
Drug: Oxaliplatin, Capecitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Agent, DOSE AND SCHEDULE (28-days cycle):~Oxaliplatin 85 mg/m2 IV on days 1 and 15 Capecitabine 1500 mg PO BID on days 1-7 and 15-21
Study: NCT02964247
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide placebo given s.c. once daily, gradually titrated to 1.8 mg/day as an add-on to the subject's stable pre-trial SGLT2 inhibitor ± metformin for 26 weeks
Study: NCT04720105
Drug: Duobrii®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duobrii® (halobetasol propionate 0.01%/tazarotene 0.045% lotion, HP/TAZ) will be provided at weeks 0,2,8,16 for a total of 24 weeks.
Study: NCT02205073
Drug: Placebo RD + AVP SD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (matching to study drug) repeat doses + intranasal AVP single dose
Study: NCT02205073
Drug: Placebo RD + Placebo SD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (matching to study drug) repeat doses + intranasal Placebo (matching to intranasal AVP) single dose
Study: NCT01869933
Drug: OC-10X
Normalized name: OC 8 Adult Acne
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01156545
Drug: BIBW 2992
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIBW 2992 40mg, once a day, oral intake, every day
Study: NCT01156545
Drug: simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: simvastatin 40mg, once a day, oral intake, every day.
Study: NCT01796678
Drug: Arginine
Normalized name: Arginine
DrugBank: Arginine (DB00125)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01796678
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline or Sugar pill was given as placebo
Study: NCT02696291
Drug: UV-4B Y mg (dose to be determined) oral solution
Normalized name: Y
Approvals — FDA: no, EMA: no, PMDA: no
Description: UV-4B Y mg (dose to be determined) oral solution administered TID (every 8 ± 0.5 hours) for 7 days
Study: NCT01987440
Drug: lubricating gel
Normalized name: Via Moisturizer For Her Lubricating Gel
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00479986
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02508623
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 1 tablet BID for 60 days
Study: NCT01161069
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in oral solution, given once daily for 14 days
Study: NCT04537884
Drug: UBX1325
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational drug intravitreal injection
Study: NCT05702333
Drug: Epinephrine Norepinephrine Dobutamine Dopamine Levosimendan
Normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vasoactive-inotropic drugs were administered according to clinical decision of the doctor in charge.
Study: NCT02092376
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04430959
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan placebo-matching tablets, orally, once daily for 4 weeks
Study: NCT03758664
Drug: ICP-192
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: ICP-192 Dose levels will be escalated following accelerated titration and modified 3+3 dose escalation scheme,
Study: NCT02147041
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02338648
Drug: SUN-131 1.5% TDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active transdermal patch
Study: NCT02338648
Drug: Placebo TDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo transdermal patch for blinding
Study: NCT04045769
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 tablets of placebo to be administered orally
Study: NCT00000525
Drug: chlorthalidone
Normalized name: Chlorthalidone
DrugBank: Chlorthalidone (DB00310)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00314704
Drug: dopamine versus norepinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04413786
Drug: placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: intranasal administration of placebo (24IU)
Study: NCT00764881
Drug: EV/DNG (Qlaira, BAY86-5027, SH T00658ID)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estradiol valerate (EV) and dienogest (DNG). Sequential 4-phasic regimen. Daily oral administration of one encapsulated SH T00658ID for 28 days per cycle, for 6 treatment cycles: Days 1-2, 3.0 mg EV; Days 3-7, 2.0 mg EV+2.0 mg DNG; Days 8-24, 2.0 mg EV+3.0 mg DNG; Days 25-26, 1.0 mg EV; Days 27-28, placebo, encapsulated for blinding purpose